Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANDA VI: Sivelestat in Cardiovascular Surgery
NCT06195267Recruiting
- Sponsor
- Nanjing Medical University
- Start
- Jul 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of sivelestat in Systemic Inflammatory Response Syndrome (SIRS) and multiple organ dysfunction syndrome (MODS) (2 arms), sponsored by Nanjing Medical University. Primary endpoint: Highest Sequential Organ Failure Assessment Score at 7 days. Started Jul 2024; status: recruiting.
02
Drugs
sivelestat
03
Conditions
Systemic Inflammatory Response Syndrome (SIRS)multiple organ dysfunction syndrome (MODS)
Beyond the preview
Go deeper on NCT06195267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06195267.